Depression - Articles - Page 7

Expert Q&A

Substance-Induced Depression: Diagnosis and Treatment

April 1, 2023

Bryan K. Tolliver, MD, PhD

Associate professor, Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina. Charleston, SC.

Dr. Tolliver has no financial relationships with companies related to this material.

“When tailoring medication choice, a careful history can guide you. If I’m treating a patient who drinks excessively at night to sleep or who struggles with insomnia when they try to stop drinking, I’ll start with a sedating antidepressant like mirtazapine. That’s not an evidence-based decision, it’s a clinical decision that I think can be helpful.”

Dr. Tolliver gives us a framework to understand the relation between depression, substance use, and substance-induced mood disorders.

Expert Q&A

Herbal Therapies for Depression

March 8, 2023

Scott Mendelson, MD, PhD

Scott Mendelson, MD, PhD.

Recently retired after 25 years of practicing inpatient and outpatient psychiatry in community and VA hospitals. He is the author of several psychiatric textbooks including Herbal Treatment of Major Depression (CRC Press, 2019) and Herbal Treatment of Anxiety (CRC Press, 2022).

Dr. Mendelson has no financial relationships with companies related to this material.

Scott Mendelson shows us how to use the top 3 herbal therapies for depression--namely, St. John’s wort, curcumin, and saffron.

Ketamine Comes Home

February 26, 2023

Kellie Newsome, PMHNP and Chris Aiken, MD

Online clinics delivered at-home ketamine throughout the pandemic, and we’re just becoming aware of the consequences.

Expert Q&A

Prolonged Grief Disorder

January 30, 2023

M. Katherine Shear, MD

M. Katherine Shear, MD

Marion E. Kenworthy Professor of Psychiatry at Columbia School of Social Work and Vagelos College of Physicians and Surgeons, New York, NY.

Dr. Shear has no financial relationships with companies related to this material.

Prolonged grief disorder is the new edition in DSM-5-TR. Katherine Shear explains how it differs from depression and PTSD and outlines a treatment approach.

Management of Depression and Neurocognitive Impairment in Patients With HIV

January 15, 2023

Victoria Hendrick, MD and Prabhjot Gill

Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications.

EXPERT Q&A

Psychiatric Issues in Organ Transplantation

January 2, 2023

Paula C. Zimbrean, MD, FAPA, FACLP

Paula C. Zimbrean, MD, FAPA, FACLP

Associate professor of psychiatry and surgery (transplant), Yale University School of Medicine; Chair, Transplant Psychiatry Special Interest Group, Academy of Consultation Psychiatry. New Haven, CT.

Dr. Zimbrean has consulted for Ultragenyx and Vivet Therapeutics, and has consulted and advised for Alexion. Relevant financial relationships listed for the author have been mitigated.

Growing numbers of patients receive organ transplants every year. This Q&A reviews the unique considerations that arise when these patients require psychiatric care.

CLINICAL UPDATE

Management of Depression and Neurocognitive Impairment in Patients With HIV

January 2, 2023

Garrett Rossi, MD.

Garrett Rossi, MD. Inpatient/consult attending psychiatrist, AtlantiCare Regional Medical Center. Pomona, NJ.
Dr. Rossi has no financial relationships with companies related to this material.

Strategies for HIV-associated mood and cognitive changes

CLINICAL UPDATE

Viibryd Goes Generic, But Is It Worth Prescribing?

January 1, 2023

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has no financial relationships with companies related to this material.

Goodbye Viibryd, hello vilazodone. This novel medication has missed the mark in a lot of trials, but it still has a narrow niche in the crowded field of antidepressants.

Using SAMe in Clinical Practice

November 15, 2022

Garrett Rossi, MD.

0.50 CME Credits. Learn how to prescribe SAMe and how to dose it effectively to achieve the desired result.

CARLAT WEBINAR

Management of Depression During Postpartum and Breastfeeding

November 15, 2022

Victoria Hendrick, MD

0.50 CME Credits. Women who have postpartum depression can find reassurance in knowing there are four evidence-based treatments that are safe for them and their babies.